GSK Purinethol Labeling Should Mention Tests For TPMT Enzyme Activity
Executive Summary
GlaxoSmithKline's Purinethol (6-mercaptopurine) labeling should mention the availability of tests for TPMT enzyme deficiency but should not specify how and when they should be used, FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee said at its July 15 meeting
You may also be interested in...
FDA Pharmacogenomics Advisory Committee Will Oversee Data Submissions
FDA is forming a pharmacogenomics advisory committee to handle voluntary genomic data submissions, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko, PhD, said
FDA Pharmacogenomics Advisory Committee Will Oversee Data Submissions
FDA is forming a pharmacogenomics advisory committee to handle voluntary genomic data submissions, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko, PhD, said
Pharmacogenetic Test Should Be Added To 6-MP Label, FDA Cmte. Says
GlaxoSmithKline's Purinethol (mercaptopurine) should include labeling recommending use of pharmacogenetic testing to guide dosing, the Clinical Pharmacology Subcommittee of FDA's Pharmaceutical Science Advisory Committee concluded at its Oct. 23 meeting